GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The FTSE 100 closed down 59.98 points at 8159.63 as traders digest Chancellor Rachel Reeves's Budget today. Among the ...

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

where excellent research and the NHS’s clinical resources combine with the talent generated by the many innovative bioscience companies that call Cambridge home. Through this very important ...

GSK sued Moderna over the shots in Delaware federal ... For all of 2023, Moderna’s Spikevax brought home $6.7 billion compared to Comirnaty’s $11.2 billion. Both numbers marked a more than ...

Pavan Kumar BVS leads INL's mission to innovate and expand in the battery sector and home-care market sustainably.

GSK and Immunocore hope the TCRs can prove to ... lung and ovarian cancers. Even closer to home is Adaptimmune - a kind of sister company to Immunocore, the companies sharing common management ...

and the Knowledge Quarter around King's Cross and Euston - home to the Wellcome Trust - and museums and tech companies, including Google. It will allow swift transport links to GSK's main R&D ...